Zoledronic acid effective as treatment for bone complications in prostate cancer patients

被引：0
|
作者：
不详
机构：
来源：
ONCOLOGY-NEW YORK | 2002年 / 16卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1202 / 1202
页数：1
相关论文
共 50 条
  • [21] Efficacy of zoledronic acid in the prevention of bone metastases in patients with locally advanced prostate cancer
    Musaev, T. N.
    Zeinalov, B. S.
    Kerimov, A. Kh.
    Guliev, F. A.
    Musaev, I. N.
    Alizade, A. M.
    Adzhalov, O. V.
    [J]. ONKOUROLOGIYA, 2011, 7 (01): : 62 - 65
  • [22] ZOLEDRONIC ACID IS COST EFFECTIVE FOR THE PREVENTION OF SKELETAL-RELATED EVENTS IN PATIENTS WITH PROSTATE CANCER AND BONE METASTASES IN FRANCE AND GERMANY
    Meijboom, Marjan
    Botteman, Marc F.
    Kaura, Satyin
    [J]. JOURNAL OF UROLOGY, 2009, 181 (04): : 295 - 295
  • [23] Efficacy of Combined Androgen Blockade with Zoledronic Acid Treatment in Prostate Cancer with Bone Metastasis: The ZABTON-PC (Zoledronic Acid/Androgen Blockade Trial on Prostate Cancer) Study
    Ueno, Satoru
    Mizokami, Atsushi
    Fukagai, Takashi
    Fujimoto, Naohiro
    Oh-Oka, Hitoshi
    Kondo, Yukihiro
    Arai, Gaku
    Ide, Hisamitsu
    Horie, Shigeo
    Ueki, Osamu
    Kawaguchi, Kouhei
    Shimamura, Masayoshi
    Orito, Matsuo
    Ishida, Takeyuki
    Ikeda, Daisuke
    Namiki, Mikio
    [J]. ANTICANCER RESEARCH, 2013, 33 (09) : 3837 - 3844
  • [24] Efficacy of combined androgen blockade with zoledronic acid treatment in prostate cancer with bone metastasis: The Zoledronic Acid/Androgen Blockade Trial on Prostate Cancer (Zabton-PC) study
    Ueno, Satoru
    Mizokami, Atsushi
    Fukagai, Takashi
    Fujimoto, Naohiro
    Ohoka, Hitoshi
    Kondo, Yukihiro
    Arai, Gaku
    Ide, Hisamitsu
    Namiki, Mikio
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [25] Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metastases in Patients With Cancer
    Van Poznak, Catherine H.
    Unger, Joseph M.
    Darke, Amy K.
    Moinpour, Carol
    Bagramian, Robert A.
    Schubert, Mark M.
    Hansen, Lisa Kathryn
    Floyd, Justin D.
    Dakhil, Shaker R.
    Lew, Danika L.
    Wade, James Lloyd, III
    Fisch, Michael J.
    Henry, N. Lynn
    Hershman, Dawn L.
    Gralow, Julie
    [J]. JAMA ONCOLOGY, 2021, 7 (02) : 246 - 254
  • [26] PROGNOSTIC IMPACT OF ZOLEDRONIC ACID ON BIOCHEMICAL RELAPSE IN TREATMENT-NAIVE PATIENTS WITH BONE-METASTATIC PROSTATE CANCER
    Matsuyama, Hideyasu
    Nozawa, Masahiro
    Inagaki, Takeshi
    Nagao, Kazuhiro
    Hara, Isao
    Uemura, Hirotsugu
    [J]. JOURNAL OF UROLOGY, 2012, 187 (04): : E312 - E312
  • [27] Continuing benefit of zoledronic acid for the prevention of skeletal complications in breast cancer patients with bone metastases
    不详
    [J]. BREAST, 2005, 14 : S45 - S46
  • [28] Continuing benefit of zoledronic acid for the prevention of skeletal complications in breast cancer patients with bone metastases
    Rosen, L.
    Gordon, D.
    Chen, Y. M.
    [J]. CANCER TREATMENT REVIEWS, 2006, 32 : S43 - S43
  • [29] Effect of zoledronic acid and biochemical relapse in treatment-naive patients with bone-metastatic prostate cancer.
    Matsuyama, Hideyasu
    Nozawa, Masahiro
    Inagaki, Takeshi
    Nagao, Kazuhiro
    Hara, Isao
    Uemura, Hirotsugu
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [30] Cancer treatment-induced bone less (CTIBL) in prostate cancer: Pathophysiology, preclinical findings, and treatment with zoledronic acid
    Guise, TA
    Eastham, JA
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2004, 3 (05) : 46 - 54
12345